Navigation Links
Gene mutation increases thromboembolism risk in women taking tamoxifen

Women taking tamoxifen for early-stage breast cancer who developed blood clots were more likely to carry a gene mutation for clotting than women taking tamoxifen who did not develop blood clots, according to an online study published June 16 in The Journal of the National Cancer Institute.

Tamoxifen is a widely-used breast cancer treatment after surgery for pre and post menopausal patients with hormone receptor-positive breast cancer. One of the most serious complications of tamoxifen usage is the development of blood clots, or thromboembolic events (TEs). Previous studies have shown that use of tamoxifen increases the risk of TEs in healthy women twofold, and that in women aged 50 and above, it is associated with even greater risk. The genetic mutation Factor V Leiden (FVL) is the most common inherited clotting factor mutation and also causes increased thrombosis risk.

To determine if having the Factor V Leiden genetic mutation increases the risk of thromboembolisms among women taking tamoxifen, Judy E. Garber, M.D. of the Dana-Farber Cancer Institute, and colleagues at the National Cancer Institute's Cancer and Leukemia Group B (CALGB) looked at 412 women who received the drug as adjuvant treatment for stage I, II, or IIIA breast cancer, between January 1999 and April 2005. The women, whose median age was 64, included 141 patients who developed TEs and 271 who did not.

The researchers found that women who had experienced a thromboembolism while taking tamoxifen were nearly five times more likely to carry the FVL mutation compared with the women who did not develop a thromboembolism. This result differed from previous studies, which found no associated risk of TEs or an increased presence of FVLs among women at risk of breast cancer, but who did not actually have the disease.

The researchers concluded that the presence of breast cancer may influence the occurrence of TEs among patients taking tamoxifen. Chemotherapy is also thought to increase the risk of TEs by decreasing coagulation inhibitors and damaging vascular endothelium. However, even though half the women in this study had also received chemotherapy, the study showed no statistically significant difference in chemotherapy exposure between the women who developed TEs and those who did not. So chemotherapy, the researchers concluded, was unlikely to explain the prevalence of the FVL mutation among women with TEs in this study. The risk of TE was also associated with smoking and family and personal history of TEs.

The researchers also concluded that: "These data may prove useful to women who must decide between tamoxifen and an effective, essentially non-thrombogenic, alternative adjuvant therapy for breast cancer, such as aromatase inhibitors for postmenopausal women and gonadotropin-releasing hormone analogs or oophorectomy for premenopausal women."

According to the authors, the study's limitations include lack of family history data on TE and other hereditary factors leading to coagulopathies. The researchers also did not collect data on other potential TE risk factors, such as body mass index and recent surgery.

In an accompanying editorial, Jack Cuzick, Ph.D., of the Wolfson Institute of Preventive Medicine at Queen Mary University of London, said that why the FVL mutation is associated with TEs among breast cancer patients taking tamoxifen but not among people taking tamoxifen preventively "remains a mystery."

"Continued follow-up and research on the relationship between the FVL mutation and tamoxifen, especially in the prevention setting, will be the only way to clarify these apparently contradictory settings," Cuzick said.


Contact: Kristine Crane
Journal of the National Cancer Institute

Related medicine news :

1. Gene Mutations Behind Brain Reduction
2. Single gene mutation induces endometrial cancer
3. Genetic Mutation Linked to Prostate Cancer in Blacks
4. Gene Mutations Identified for Charcot-Marie-Tooth Syndrome
5. Study shows that mutations in 1 gene cause many cancers
6. Parkinsons Linked to Genetic Mutation
7. Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast
8. Gene Mutations Up Risk for Cancer in Opposite Breast
9. Gene Mutation Ups Risk of Sudden Death in People with Epilepsy
10. Heart Disease Among Childhood Cancer Survivors Tied to Gene Mutations
11. New research indicates that DNA sequence itself influences mutation rate
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving ... dropped below 10,000 for the first time since 2011. In 2014, there were 9,967 ... data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent breast reconstruction ... incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my ... RECOVERY BRA for added comfort and support. The bra is easier to put ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Executive Officer Doug Godshall is scheduled to ... Healthcare Conference on December 1, 2015 at 3:00 p.m. ... New York . ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... 2015 F1000Workspace - a research ... it was launched just six months ago. --> ... platform for scientists - since it was launched just six ... loaded on to F1000Workspace - a research collaboration, ... was launched just six months ago. --> ...
Breaking Medicine Technology: